Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[211At]astato-α-methyl-L-phenylalanine in tumor-bearing model.

INTRODUCTION Targeted α-radionuclide therapy has attracted attention as a promising therapy for refractory cancers. However, the application is limited to certain types of cancer. Since L-type amino acid transporter 1 (LAT1) is highly expressed in various human cancers, we prepared an LAT1-selective α-radionuclide-labeled amino acid analog, 2-[211At]astato-α-methyl-L-phenylalanine (2-[211At]AAMP), and evaluated its potential as a therapeutic agent. METHODS 2-[211At]AAMP was prepared from the stannyl precursor. Stability of 2-[211At]AAMP was evaluated both in vitro and in vivo. In vitro studies using an LAT1-expressing human ovarian cancer cell line, SKOV3, were performed to evaluate cellular uptake and cytotoxicity of 2-[211At]AAMP. Biodistribution and therapeutic studies in SKOV3-bearing mice were performed after intravenous injection of 2-[211At]AAMP. RESULTS 2-[211At]AAMP was stable in murine plasma in vitro and excreted intact into urine. Cellular uptake of 2-[211At]AAMP was inhibited by treatment with an LAT1-selective inhibitor. After 24 h incubation, 2-[211At]AAMP suppressed clonogenic growth at 10 kBq/ml, and induced cell death and DNA double-strand breaks at 25 kBq/ml. When injected into mice, 2-[211At]AAMP exhibited peak accumulation in the tumor at 30 min postinjection, and radioactivity levels in the tumor were retained up to 60 min. The majority of the radioactivity was rapidly eliminated from the body into urine in an intact form immediately after injection. 2-[211At]AAMP significantly improved the survival of mice (P < 0.05) without serious side effects. CONCLUSION 2-[211At]AAMP showed α-radiation-dependent cellular growth inhibition after it was taken up via LAT1. In addition, 2-[211At]AAMP had a beneficial effect on survival in vivo. These findings suggest that 2-[211At]AAMP would be useful for the treatment of LAT1-positive cancer. ADVANCES IN KNOWLEDGE AND IMPLICATIONS FOR PATIENT CARE This is the first report of an LAT1-targeting radiopharmaceutical for α-radionuclide therapy; this agent would be applicable for the treatment of various types of cancer.

[1]  T. Watabe,et al.  Targeted alpha therapy using astatine (211At)-labeled phenylalanine: A preclinical study in glioma bearing mice , 2020, Oncotarget.

[2]  Y. Tsushima,et al.  Novel 18F-labeled α-methyl-phenylalanine derivative with high tumor accumulation and ideal pharmacokinetics for tumor specific imaging. , 2019, Molecular pharmaceutics.

[3]  Pascal Häfliger,et al.  The L-Type Amino Acid Transporter LAT1—An Emerging Target in Cancer , 2019, International journal of molecular sciences.

[4]  M. McDevitt,et al.  Targeted and Nontargeted α-Particle Therapies. , 2018, Annual review of biomedical engineering.

[5]  J. Engle,et al.  Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations , 2018, Targeted Oncology.

[6]  B. Allen,et al.  Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. , 2018, Critical reviews in oncology/hematology.

[7]  C. Kuntner,et al.  Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. , 2016, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[8]  F. Mottaghy,et al.  225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer , 2016, The Journal of Nuclear Medicine.

[9]  Y. Tsushima,et al.  Development of a Widely Usable Amino Acid Tracer: 76Br-α-Methyl-Phenylalanine for Tumor PET Imaging , 2015, The Journal of Nuclear Medicine.

[10]  G. Taucher‐Scholz,et al.  Nanoscale analysis of clustered DNA damage after high-LET irradiation by quantitative electron microscopy--the heavy burden to repair. , 2015, DNA repair.

[11]  U. Haberkorn,et al.  213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Tsutomu Yoshida,et al.  Unique and selective expression of L-amino acid transporter 1 in human tissue as well as being an aspect of oncofetal protein. , 2014, Histology and histopathology.

[13]  J. Nielsen,et al.  Analysis of the Human Tissue-specific Expression by Genome-wide Integration of Transcriptomics and Antibody-based Proteomics* , 2013, Molecular & Cellular Proteomics.

[14]  Eva Forssell-Aronsson,et al.  Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats. , 2013, Cancer biotherapy & radiopharmaceuticals.

[15]  J. Krauss,et al.  Systemic treatment with 4-211At - phenylalanine enhances survival of rats with intracranial glioblastoma , 2013, Nuklearmedizin.

[16]  I. Rooman,et al.  Amino acid transporters expression in acinar cells is changed during acute pancreatitis. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[17]  Y. Tsushima,et al.  Biological evaluation of 3-[18F]fluoro-α-methyl-d-tyrosine (d-[18F]FAMT) as a novel amino acid tracer for positron emission tomography , 2013, Annals of Nuclear Medicine.

[18]  Y. Kanai,et al.  Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With α-Alkyl Moieties , 2012, Journal of Pharmacological Sciences.

[19]  H. Hanaoka,et al.  Preparation and biological evaluation of 3-[(76)Br]bromo-α-methyl-L-tyrosine, a novel tyrosine analog for positron emission tomography imaging of tumors. , 2011, Nuclear medicine and biology.

[20]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[21]  W. Knapp,et al.  Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[22]  Syuichi Nakajima,et al.  Pharmacokinetics of 3-[125I]iodo-alpha-methyl-L-tyrosine, a tumor imaging agent, after probenecid loading in mice implanted with colon cancer DLD-1 cells. , 2007, Nuclear medicine and biology.

[23]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[24]  K. Langen,et al.  3-[123I]Iodo-α-methyl-L-tyrosine: uptake mechanisms and clinical applications , 2002 .

[25]  C. Meier,et al.  Activation of system L heterodimeric amino acid exchangers by intracellular substrates , 2002, The EMBO journal.

[26]  Jun Sun,et al.  CD98-mediated Links between Amino Acid Transport and β1 Integrin Distribution in Polarized Columnar Epithelia* , 2001, The Journal of Biological Chemistry.

[27]  Y. Kanai,et al.  Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. , 2001, Biochimica et biophysica acta.

[28]  J Aoki,et al.  Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. , 2001, Radiology.

[29]  Eiji Takeda,et al.  Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity* , 1999, The Journal of Biological Chemistry.

[30]  M. Zalutsky,et al.  211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  M. Zalutsky,et al.  1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. , 1992, Bioconjugate chemistry.

[32]  P. Garg,et al.  Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment. , 1990, Cancer research.

[33]  Y. Kanai,et al.  Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters. , 2008, Journal of pharmacological sciences.